| 3RGF |
2.2 |
Crystal Structure of human CDK8/CycC |
| 4CRL |
2.4 |
Crystal structure of human CDK8-Cyclin C in complex with cortistatin A |
| 4F6S |
2.6 |
Crystal structure of human CDK8/CYCC in complex with compound 7 (1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]urea) |
| 4F6U |
2.1 |
Crystal structure of human CDK8/CYCC in complex with compound 5 (1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-3-[3-(morpholin-4-yl)propyl]urea) |
| 4F6W |
2.39 |
Crystal structure of human CDK8/CYCC in complex with compound 1 (N-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-4-[2-({[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]carbamoyl}amino)ethyl]piperazine-1-carboxamide) |
| 4F70 |
3.0 |
Crystal structure of human CDK8/CYCC in complex with compound 4 (1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-3-[2-(morpholin-4-yl)ethyl]urea) |
| 4F7J |
2.6 |
Crystal structure of human CDK8/CYCC in complex with compound 3 (1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-3-(2-hydroxyethyl)urea) |
| 4F7L |
2.9 |
Crystal structure of human CDK8/CYCC in complex with compound 2 (tert-butyl [3-({[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]carbamoyl}amino)propyl]carbamate) |
| 4F7N |
2.65 |
Crystal structure of human CDK8/CYCC in complex with compound 11 (1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-3-(5-hydroxypentyl)urea) |
| 4F7S |
2.2 |
Crystal structure of human CDK8/CYCC in the DMG-in conformation |
| 4G6L |
2.7 |
Crystal structure of human CDK8/CYCC in the DMG-in conformation |
| 5BNJ |
2.64 |
CDK8/CYCC IN COMPLEX WITH 8-{3-Chloro-5-[4-(1-methyl-1H-pyrazol-4-yl)-phenyl]-pyridin- 4-yl}-2,8-diaza-spiro[4.5]decan-1-one |
| 5CEI |
2.24 |
Crystal structure of CDK8:Cyclin C complex with compound 22 |
| 5FGK |
2.36 |
CDK8-CYCC IN COMPLEX WITH 8-[3-(3-Amino-1H-indazol-6-yl)-5-chloro- pyridine-4-yl]-2,8-diaza-spiro[4.5]decan-1-one |
| 5HBE |
2.38 |
CDK8-CYCC IN COMPLEX WITH 8-[3-Chloro-5-(1-methyl-2,2-dioxo-2, 3-dihydro-1H-2l6-benzo[c]isothiazol-5-yl)-pyridin- 4-yl]-1-oxa-3,8-diaza-spiro[4.5]decan-2-one |
| 5HBH |
2.5 |
CDK8-CYCC IN COMPLEX WITH 5-{5-Chloro-4-[1-(2-methoxy-ethyl)-1,8-diaza-spiro[4.5]dec-8-yl]-pyridin-3-yl}-1-methyl-1,3-dihydro-benzo[c]isothiazole 2,2-dioxide |
| 5HBJ |
3.0 |
CDK8-CYCC IN COMPLEX WITH 8-[2-Amino-3-chloro-5-(1-methyl-1H-indazol-5-yl)-pyridin-4-yl]-2,8-diaza-spiro[4.5]decan-1-one |
| 5HNB |
2.35 |
CDK8-CYCC IN COMPLEX WITH [6-Hydroxy-3-(3-methyl-benzyl)-1H-indazol-5-yl]-((S)-3-hydroxy-pyrrolidin-1-yl)-methanone |
| 5HVY |
2.39 |
CDK8/CYCC IN COMPLEX WITH COMPOUND 20 |
| 5I5Z |
2.6 |
CDK8-CYCC IN COMPLEX WITH 8-(1-Methyl-2,2-dioxo-2,3-dihydro-1H-2l6-benzo[c]isothiazol-5-yl)-[1,6]naphthyridine-2-carboxylic acid methylamide |
| 5ICP |
2.18 |
CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-Chloro-phenyl)-pyrrolidin-1-yl]-(5-methyl-imidazo[5,1-b][1,3,4]thiadiazol-2-yl)-methanone |
| 5IDN |
2.26 |
CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-Chloro-phenyl)-pyrrolidin-1-yl]-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-methanone |
| 5IDP |
2.65 |
CDK8-CYCC IN COMPLEX WITH (3-Amino-1H-indazol-5-yl)-[(S)-2-(4-fluoro-phenyl)-piperidin-1-yl]-methanone |
| 5XQX |
2.3 |
Human CDK8-CYCC in complex with compound 4: N-methyl-4-(4-pyridyl)-1H-pyrrole-2-carboxamide |
| 5XS2 |
2.04 |
CDK8-CYCC IN COMPLEX WITH COMPOUND 17:3-chloro-4-(4-pyridyl)-1H-pyrrole-2-carboxamide |
| 6QTG |
2.7 |
Crystal structure of human CDK8/CYCC in complex with BI-1347 |
| 6QTJ |
2.48 |
Crystal structure of human CDK8/CYCC in complex with BI 919811 |
| 6R3S |
2.19 |
CRYSTAL STRUCTURE OF CDK8-CycC IN COMPLEX WITH COMPOUND 1 |
| 6T41 |
2.45 |
CDK8/Cyclin C in complex with N-(4-chlorobenzyl)isoquinolin-4-amine |
| 6TPA |
2.8 |
CDK8/CyclinC in complex with drug ETP-50775 |
| 6Y0A |
2.19 |
CRYSTAL STRUCTURE OF CDK8-CycC IN COMPLEX WITH BI00690300 |
